MX2021010345A - Compuestos de pirazolopiridina para la inhibición de ire1. - Google Patents

Compuestos de pirazolopiridina para la inhibición de ire1.

Info

Publication number
MX2021010345A
MX2021010345A MX2021010345A MX2021010345A MX2021010345A MX 2021010345 A MX2021010345 A MX 2021010345A MX 2021010345 A MX2021010345 A MX 2021010345A MX 2021010345 A MX2021010345 A MX 2021010345A MX 2021010345 A MX2021010345 A MX 2021010345A
Authority
MX
Mexico
Prior art keywords
disease
pyrazolopyridine compounds
compounds
disorder
ire1
Prior art date
Application number
MX2021010345A
Other languages
English (en)
Inventor
George Hynd
Jon Sutton
Richard Keenan
Original Assignee
Optikira Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optikira Llc filed Critical Optikira Llc
Publication of MX2021010345A publication Critical patent/MX2021010345A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona compuestos de pirazolopiridina, composiciones y métodos novedosos para tratar o prevenir una enfermedad o trastorno relacionado con IRE1a; en ciertas modalidades, la enfermedad o trastorno se selecciona del grupo que consiste en una enfermedad neurodegenerativa, una enfermedad desmielinizante, cáncer, una enfermedad ocular, una enfermedad fibrótica, y diabetes.
MX2021010345A 2019-02-27 2020-02-27 Compuestos de pirazolopiridina para la inhibición de ire1. MX2021010345A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811237P 2019-02-27 2019-02-27
US201962813975P 2019-03-05 2019-03-05
PCT/US2020/020162 WO2020176765A1 (en) 2019-02-27 2020-02-27 Pyrazolopyridine compounds for ire1 inhibition

Publications (1)

Publication Number Publication Date
MX2021010345A true MX2021010345A (es) 2021-12-15

Family

ID=72238956

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010345A MX2021010345A (es) 2019-02-27 2020-02-27 Compuestos de pirazolopiridina para la inhibición de ire1.

Country Status (12)

Country Link
US (1) US20220153734A1 (es)
EP (1) EP3930718A4 (es)
JP (1) JP2022521784A (es)
KR (1) KR20210139280A (es)
CN (1) CN113795254B (es)
AU (1) AU2020228644A1 (es)
BR (1) BR112021016974A2 (es)
CA (1) CA3131388A1 (es)
IL (1) IL285794A (es)
MX (1) MX2021010345A (es)
SG (1) SG11202109194UA (es)
WO (1) WO2020176765A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4192462A4 (en) * 2020-08-07 2024-09-04 Optikira Llc PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING THEM

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US8980899B2 (en) * 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
CN104995192A (zh) * 2012-09-26 2015-10-21 加利福尼亚大学董事会 Ire1的调节
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2017152126A1 (en) * 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
WO2018161033A1 (en) * 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CA3064837A1 (en) * 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
AU2018326721B2 (en) * 2017-09-01 2022-12-01 Optikira, LLC Compounds and compositions for IRE1 inhibition
EP4192462A4 (en) * 2020-08-07 2024-09-04 Optikira Llc PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING THEM

Also Published As

Publication number Publication date
CN113795254B (zh) 2024-08-09
BR112021016974A2 (pt) 2021-11-30
EP3930718A1 (en) 2022-01-05
JP2022521784A (ja) 2022-04-12
US20220153734A1 (en) 2022-05-19
AU2020228644A1 (en) 2021-09-23
CN113795254A (zh) 2021-12-14
CA3131388A1 (en) 2020-09-03
KR20210139280A (ko) 2021-11-22
EP3930718A4 (en) 2022-10-05
IL285794A (en) 2021-10-31
WO2020176765A1 (en) 2020-09-03
SG11202109194UA (en) 2021-09-29

Similar Documents

Publication Publication Date Title
MX2020002322A (es) Compuestos y composiciones para la inhibicion de ire1.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
NZ746554A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
PH12021550558A1 (en) Modulators of pnpla3 expression
MX2024000780A (es) Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon.
MX2020012497A (es) Moduladores de la expresion de apol1.
MX2021007503A (es) Moduladores de la expresion de hsd17b13.
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
MX2021008094A (es) Metodos y composiciones para el tratamiento del cancer.
MX2020009147A (es) Moduladores de la expresion de irf4.
MX2023013912A (es) Metodos para inhibir ras.
PH12021551053A1 (en) Modulators of irf5 expression
EA202191358A1 (ru) Новые соединения и их применение в лечении
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2022007626A (es) Combinaciones.
MX2020007369A (es) Moduladores de la expresion de dnm2.
MX2021010345A (es) Compuestos de pirazolopiridina para la inhibición de ire1.
MX2020012292A (es) Compuestos para el tratamiento de cáncer de pancreas.
MX2022007623A (es) Combinaciones.
MX2020010721A (es) Moduladores de la expresion de ezh2.
JOP20210107A1 (ar) مضمنات التعبير عن foxp3
EP3984553A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER